Ketamine Research and Policy Updates
News and research summaries on evidence, regulation, FDA and DEA actions, trials, and access relevant to oral ketamine patients and providers.
What belongs here
Current research, policy, FDA, DEA, trial, and access updates with patient-facing context and links to primary sources when available.
What to read next
Use news for context, then move to the evergreen how-it-works, dosing, or safety hubs for durable treatment planning information.
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.
Featured
3 articlesVA Ketamine Therapy Cuts Threaten Veterans' Relief
Veterans relying on ketamine programs for PTSD relief face uncertainty as funding cuts loom. Here's what oral ketamine tablets mean for access.
Wisconsin Man's Depression Story: What Oral Ketamine Offers
A Wisconsin man's ketamine treatment success raises awareness of oral tablet options for depression. What patients should know before starting.
Study: Ketamine Relieves Treatment-Resistant Depression
New research highlights ketamine's potential against resistant depression and suicidal thoughts. Here's what tablet users need to know about access and dosing.
NRx Pharma Gets FDA Expanded Access for Ketamine Protocol
NRx Pharmaceuticals received an FDA Expanded Access grant for its ketamine-bridging treatment program. Here's what it means for patients and oral ketamine access.
Brain Scans Could Predict Ketamine Tablet Success
New research shows brain imaging may predict which depression patients will respond to ketamine tablets before treatment begins.
Expert Highlights Key Patient Considerations for Ketamine
Dr. Benjamin Brody shares crucial patient safety and treatment considerations for ketamine therapy at major psychiatric conference.
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston health clinics are expanding ketamine therapy for depression and PTSD — here's what it means for patients exploring oral ketamine tablets.
One Patient's Year With Ketamine and Experimental Care
A Guardian journalist tried ketamine and other cutting-edge depression treatments for a year. What oral ketamine patients can learn from her experience.
Study: CBT After Ketamine Cuts Depression Relapse Risk
The CBT-ENDURE trial shows adding 16 weeks of CBT to esketamine outperforms ketamine alone for depression and suicidal ideation.
Ketamine for PTSD: Workers' Comp Coverage Is Shifting
Alabama workers' comp rulings on ketamine for PTSD and depression signal a broader coverage shift. Here's what it means for oral ketamine tablet patients.
Your Antidepressant Class May Not Affect Ketamine Results
New research shows concurrent SSRI, SNRI, or other antidepressant use doesn't significantly alter ketamine outcomes — what oral ketamine tablet users need to know.
How Symptom Tracking Reshapes Oral Ketamine Dosing for TRD
Regular symptom tracking and faster dose adjustments drive TRD remission sooner. Here's what that means for oral ketamine tablet users.
NMDA Antagonist Side Effects: What Tablet Users Need to Know
New clinical data on NMDA antagonist side effects and dropout rates has real implications for oral ketamine tablet users. Here's what the research means for you.
FDA Signals Support for Preservative-Free Ketamine
The FDA has issued a positive response on preservative-free ketamine formulations. Here's what this regulatory shift means for oral ketamine tablet patients.
Why Patients Quit Ketamine Early—And How Tablets Factor In
New clinical data on NMDA antagonist dropout rates reveals how side effect management and route of administration affect treatment-resistant depression outcomes.
TRD Guidelines Spotlight Ketamine's Growing Role
Psychiatric Times highlights optimizing TRD treatments in 2026. Here's what it means for patients using oral ketamine tablets for depression.
Oral Ketamine Side Effects: What New TRD Data Tells Us
New clinical guidance on NMDA antagonist side effects and discontinuation rates offers key lessons for oral ketamine tablet users managing treatment-resistant depression.
NRx's Preservative-Free Ketamine Moves Closer to FDA OK
NRx Pharmaceuticals reports progress on its FDA application for preservative-free ketamine. Here's what this could mean for tablets, dosing, and patient access.
Trump EO on Psychedelics: What It Means for Ketamine
President Trump signed an executive order accelerating psychedelic research and access. Here's what oral ketamine tablet patients need to know about what changes.
NMDA Antagonist Side Effects: What Tablet Users Should Know
New research in Psychiatric Times breaks down side effect profiles and discontinuation rates for NMDA antagonists — here's what it means for oral ketamine tablet users.
Ketamine Side Effects & Dropout Rates: What Data Says
New analysis in Psychiatric Times urges data-driven ketamine dosing. Here's what the side-effect and dropout data means for oral tablet users.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights how glutamate-targeting drugs like esketamine and ketamine are reshaping treatment-resistant depression care. Here's what it means for oral ketamine users.
Faster TRD Remission: What Dose Optimization Means
New clinical guidance on TRD care emphasizes rapid dose adjustment and symptom tracking — here's what it means for oral ketamine tablet patients.
Glutamate Pathway Treatments Reshaping TRD Care
New research highlights glutamate-based therapies like esketamine and ketamine tablets for treatment-resistant depression. Here's what it means for oral ketamine users.
Insurance Gaps Push Patients Toward Oral Ketamine
Ketamine insurance claim denied? How oral ketamine tablets offer an affordable depression treatment path, plus appeals tips and cash-pay tablet pricing.
How Doctors Choose TRD Treatments in 2026
How clinicians choose ketamine treatments for treatment-resistant depression in 2026, including when oral tablets are picked over IV, IM, or nasal spray.
Esketamine for Treatment-Resistant Depression in 2026
Esketamine (Spravato) for treatment-resistant depression compared to ketamine tablets: efficacy, monitoring, cost, and which oral or nasal option fits.
Glutamate Pathway Drugs Are Reshaping TRD Care
How ketamine acts on the glutamate pathway in treatment-resistant depression and why oral tablet therapy targets the same NMDA receptors as IV ketamine.
Why Remission—Not Just Relief—Changes Ketamine Care
New clinical guidance pushes beyond symptom reduction toward full remission in TRD. Here's what that means for oral ketamine tablet users.
Ketamine's Role in Treatment-Resistant Depression Care
Psychiatric Times highlights ketamine among top TRD approaches. Here's what oral ketamine tablet users need to know about access and dosing.
BPL-003 Shows Sustained TRD Relief in Phase 2a Trial
Beckley Psytech's BPL-003 phase 2a part 2 data shows lasting symptom reduction in treatment-resistant depression — what it means for the TRD landscape.
How Ketamine Tablets Are Absorbed in the Gut: The Science of GI Absorption
How ketamine tablets absorb in the gut: dietary fat effects, antacid interactions, first-pass metabolism, and timing rules to protect oral bioavailability.
Ketamine Tablet Adherence: What Research Says About Staying on Treatment
A review of research on patient adherence to oral ketamine tablet treatment, including barriers, predictors of success, and strategies to improve compliance.
Ketamine Tablet as Antidepressant Augmentation
Research on combining ketamine tablet with SSRIs, SNRIs, and other antidepressants — pharmacological rationale, evidence for augmentation protocols, and interaction considerations.
ketamine tablet Pain Research
Systematic review of ketamine tablet pain research — systematic reviews, dose-response relationships, specific pain conditions, and what the evidence shows for analgesic use.
ketamine tablet Research in Older Adults
Review of clinical research on oral and IV ketamine in older adults — cognitive safety concerns, dosing adjustments, emerging evidence, and what Spravato trials in elderly patients showed.
ketamine tablet in Pediatric Patients
Evidence, safety considerations, dosing data, and current clinical use of ketamine tablet in pediatric patients — from anesthetic premedication to emerging psychiatric applications.
Oral vs. IV Ketamine: Comparative Research
Evidence-based comparison of oral and IV ketamine — efficacy, tolerability, dose equivalence, pharmacokinetics, and when each route is preferable clinically.
Long-Term Outcomes of Ketamine Tablet Therapy
What the research shows about 6-month and 1-year outcomes of ketamine tablet therapy — response durability, relapse rates, safety over time, and dose stability findings.
Ketamine Tablet Bioavailability Studies
Published pharmacokinetic research on ketamine tablet absorption — bioavailability data, factors affecting absorption, and implications for clinical dosing.
Key Clinical Trials on Ketamine Tablet
Overview of the most important clinical trials on ketamine tablet — major RCTs, open-label studies, the STAR*D context, and what current research tells us about efficacy.